Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep;23(9):2036-49.
doi: 10.1007/s11095-006-9067-5. Epub 2006 Aug 12.

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

Affiliations

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

Karl Brendel et al. Pharm Res. 2006 Sep.

Abstract

Purpose: The aim of this study is to define and illustrate metrics for the external evaluation of a population model.

Materials and methods: In this paper, several types of metrics are defined: based on observations (standardized prediction error with or without simulation and normalized prediction distribution error); based on hyperparameters (with or without simulation); based on the likelihood of the model. All the metrics described above are applied to evaluate a model built from two phase II studies of gliclazide. A real phase I dataset and two datasets simulated with the real dataset design are used as external validation datasets to show and compare how metrics are able to detect and explain potential adequacies or inadequacies of the model.

Results: Normalized prediction errors calculated without any approximation, and metrics based on hyperparameters or on objective function have good theoretical properties to be used for external model evaluation and showed satisfactory behaviour in the simulation study.

Conclusions: For external model evaluation, prediction distribution errors are recommended when the aim is to use the model to simulate data. Metrics through hyperparameters should be preferred when the aim is to compare two populations and metrics based on the objective function are useful during the model building process.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Simulated concentrations versus time for Vtrue (top) and Vfalse (bottom). The dashed lines represent the 80 % predicted interval, obtained for each time-point as the 10th and 90th percentiles of 1000 simulations under MB.
Figure 2
Figure 2
Metrics based on observations plotted versus time on Vtrue (left) and on Vfalse (right). Top: SPEY; middle: SPEYS; bottom: NPDEYS. The dashed lines represent the 95 % prediction interval for a normal distribution.
Figure 3
Figure 3
QQ-plots of the metrics based on observations versus the theoretical N(0,1) distribution for Vtrue (left) and Vfalse (right). The line y = x is shown to evaluate the adequacy between the theoretical and the observed distribution. Top: SPEY; middle: SPEYS; bottom: NPDEYS.
Figure 4
Figure 4
Histogram of the predictive distribution of simulated hyperparameters estimated using MB: for CL/F (top) and ω2CL/F (bottom). The values of the corresponding parameters found for Vtrue, Vfalse and Vreal using an independent population analysis are shown as vertical lines.
Figure 5
Figure 5
Histogram of the predictive distribution of the objective function when model MB is applied to the 1000 datasets without estimation (top) and the gain in objective function (bottom). The values of the the objective functions or of the gain found for Vtrue, Vfalse and Vreal using MB are shown as dotted lines.
Figure 6
Figure 6
Concentrations versus time for Vreal. The dashed lines represent the 80 % predicted interval, obtained for each time-point as the 10th and 90th percentiles of 1000 simulations under MB.
Figure 7
Figure 7
Metrics based on observations plotted versus time on Vreal. Top: SPEY; middle: SPEYS; bottom: NPDEYS. The dashed lines represent the 95 % prediction interval for a normal distribution.

References

    1. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol. 2000;40:67–95. - PubMed
    1. Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A. Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci. 2001;13:115–122. - PubMed
    1. Jochemsen R, Laveille C, Breimer DD. Application of pharmacokinetic/pharmacodynamic modelling and population approaches to drug development. International J of Pharmaceutical Medicine. 1999;13:243–251.
    1. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000;40:209–234. - PubMed
    1. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000;17:1335–1344. - PubMed